On November 15, 2022, Dr. Dudu Tong, R&D Director of Leman Biotech, was invited to participate in the "20+8 Industrial Cluster Exchange of Science and Technology Innovation Enterprises" held at the 2022 China High-Tech Fair by Shenzhen Angel FOF. During the event, Dr. Tong participated in a roundtable discussion along with biomedical experts from Cellbri Biotech, Rocrock Biology, and Hi-tech Investment and Venture Capital, focusing on the topic of "Cell and Gene Therapy Bringing New Opportunities". The experts and hosts explored the biomedical venture capital environment in Shenzhen, the current challenges and advancements in the field of cell and gene therapy, and the development of the cell and gene therapy industry ecosystem.
Dr. Tong discussed the current development plans and pipelines of Leman Biotech. He also engaged in a discussion with the experts on topics such as the low overall response rate and drug resistance of existing immunotherapies, as well as the role of T cell exhaustion, a bottleneck problem that limits many immunotherapies. Dr. Tong shared how Leman Biotech's core technology, Meta10, reverses T cell exhaustion through metabolic reprogramming, thereby improving the response rate and efficacy of cancer immunotherapy. He emphasized that the Meta10 technology platform has the potential to enhance all T-cell-based cancer immunotherapies and Leman Biotech hopes to collaborate with other companies in the field to drive the development of the next generation of cancer immunotherapies.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
